HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter Atadja Selected Research

Histone Deacetylases (Histone Deacetylase)

2/2014Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.
4/2012Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
7/2011Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
1/2011Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
10/2008Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
6/2008Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
6/2008Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
5/2008Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.
2/2007Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
1/2007Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter Atadja Research Topics

Disease

43Neoplasms (Cancer)
01/2022 - 01/2004
19Leukemia
10/2017 - 08/2003
12Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2020 - 04/2004
11Multiple Myeloma
10/2014 - 10/2003
7Breast Neoplasms (Breast Cancer)
04/2012 - 10/2003
5Carcinoma (Carcinomatosis)
07/2009 - 01/2006
4Adenocarcinoma
11/2012 - 01/2002
4BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/2008 - 08/2003
3Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2020 - 10/2010
3Prostatic Neoplasms (Prostate Cancer)
01/2011 - 09/2005
3Hypoxia (Hypoxemia)
01/2011 - 09/2004
3Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
11/2010 - 07/2008
2Lymphoma (Lymphomas)
01/2017 - 07/2009
2Melanoma (Melanoma, Malignant)
10/2013 - 01/2007
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/2008 - 04/2004
2Blast Crisis (Blast Phase)
02/2005 - 08/2003
1Liver Neoplasms (Liver Cancer)
10/2015
1Carcinogenesis
10/2013
1B-Cell Lymphoma (Lymphoma, B Cell)
04/2013
1Pancreatic Neoplasms (Pancreatic Cancer)
11/2012
1Hodgkin Disease (Hodgkin's Disease)
05/2012
1Triple Negative Breast Neoplasms
04/2012
1Liver Diseases (Liver Disease)
01/2011
1Bone Diseases (Bone Disease)
05/2010
1Plasmacytoma
05/2010

Drug/Important Bio-Agent (IBA)

49Histone Deacetylase InhibitorsIBA
01/2016 - 08/2003
38PanobinostatIBA
11/2020 - 02/2005
21LAQ824IBA
07/2009 - 08/2003
20Histone Deacetylases (Histone Deacetylase)IBA
02/2014 - 08/2003
18Proteins (Proteins, Gene)FDA Link
01/2020 - 08/2003
11Pharmaceutical PreparationsIBA
01/2017 - 08/2003
10Histones (Histone)IBA
10/2017 - 01/2004
6Hydroxamic Acids (Hydroxamic Acid)IBA
10/2008 - 08/2003
4Polycomb Repressive Complex 2IBA
01/2022 - 12/2006
4Lysine (L-Lysine)FDA Link
10/2017 - 09/2009
4MethyltransferasesIBA
01/2017 - 05/2008
4Heat-Shock Proteins (Heat-Shock Protein)IBA
04/2010 - 08/2004
4VorinostatFDA Link
04/2010 - 04/2008
3Bortezomib (Velcade)FDA Link
01/2020 - 05/2010
3Histone MethyltransferasesIBA
10/2015 - 12/2006
3Histone-Lysine N-MethyltransferaseIBA
10/2014 - 11/2011
3EnzymesIBA
02/2014 - 08/2009
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
04/2012 - 08/2004
3Imatinib Mesylate (Gleevec)FDA Link
06/2009 - 08/2003
3tanespimycin (17AAG)IBA
10/2008 - 02/2005
2EED226IBA
01/2022 - 01/2017
2Arsenic Trioxide (Trisenox)FDA Link
11/2020 - 01/2015
2CCAAT-Enhancer-Binding ProteinsIBA
01/2020 - 10/2010
23-deazaneplanocinIBA
11/2012 - 09/2009
2Phosphotransferases (Kinase)IBA
11/2012 - 08/2004
2Mechanistic Target of Rapamycin Complex 1IBA
11/2012 - 01/2011
2Estrogens (Estrogen)FDA Link
04/2012 - 08/2007
2Androgen Receptors (Androgen Receptor)IBA
01/2011 - 09/2005
2AndrogensIBA
01/2011 - 09/2005
2TOR Serine-Threonine KinasesIBA
01/2011 - 06/2008
2Reactive Oxygen Species (Oxygen Radicals)IBA
03/2010 - 10/2008
2SurvivinIBA
08/2009 - 09/2004
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2009 - 04/2004
2LigandsIBA
02/2009 - 04/2004
2Biological ProductsIBA
10/2008 - 09/2004
2NucleosidesIBA
10/2008 - 04/2008
2Molecular Chaperones (Chaperone, Molecular)IBA
06/2008 - 08/2004
2Proteasome InhibitorsIBA
06/2008 - 07/2005
2Estrogen Receptor alphaIBA
08/2007 - 01/2007
2trichostatin A (A 300)IBA
02/2007 - 01/2007
2Messenger RNA (mRNA)IBA
01/2007 - 08/2003
2Small Interfering RNA (siRNA)IBA
12/2006 - 07/2005
2Tyrosine Kinase InhibitorsIBA
07/2006 - 09/2004
2AcidsIBA
01/2006 - 09/2005
1Flavin-Adenine Dinucleotide (FAD)IBA
10/2017
1Peptides (Polypeptides)IBA
10/2014
1MM-401IBA
01/2014
1AntigensIBA
10/2013
1Differentiation AntigensIBA
10/2013
1Phosphatidylinositols (Phosphatidylinositol)IBA
04/2013
1moesinIBA
04/2013
1Beclin-1IBA
04/2013
1N-acetyltalosaminuronic acid (NAT)IBA
04/2013
1Methionine (L-Methionine)FDA Link
12/2012
1dactolisibIBA
11/2012
1Mechanistic Target of Rapamycin Complex 2IBA
11/2012
1Insulin-Like PeptidesIBA
04/2012
1picropodophyllinIBA
04/2012
1Chloroquine (Aralen)FDA LinkGeneric
04/2012
1Progesterone Receptors (Progesterone Receptor)IBA
04/2012
1Azacitidine (5 Azacytidine)FDA Link
01/2012
1human SMYD2 proteinIBA
11/2011
1AntibodiesIBA
06/2011
14-hydroxy-2-nonenal (4-hydroxynonenal)IBA
01/2011
1Antineoplastic Agents (Antineoplastics)IBA
01/2011
1MicroRNAs (MicroRNA)IBA
01/2011
1EverolimusFDA Link
01/2011
1SteroidsIBA
05/2010
1Drug CombinationsIBA
05/2010
1Dexamethasone (Maxidex)FDA LinkGeneric
05/2010
1Lenalidomide (CC 5013)FDA Link
05/2010
15- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA
04/2010
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2010

Therapy/Procedure

14Therapeutics
01/2017 - 10/2003
3Aftercare (After-Treatment)
07/2009 - 04/2008